Digital breast tomosynthesis market seen topping $5.31 billion by 2030

By AI, Created 1:55 PM UTC, May 25, 2026, /AGP/ – The digital breast tomosynthesis market is projected to grow from $3.12 billion in 2026 to $5.31 billion by 2030, driven by breast cancer screening demand, AI adoption and broader use of 3D imaging. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - Digital breast tomosynthesis is becoming a more important tool for breast cancer screening and diagnosis as providers look for better early detection and fewer false positives. - The market’s projected growth signals continued investment in advanced imaging systems and screening programs. - The technology is especially relevant for women with dense breast tissue, where standard 2D mammography can be harder to interpret.

What happened: - The Business Research Company projected the digital breast tomosynthesis market will rise from $2.74 billion in 2025 to $3.12 billion in 2026. - The report forecasts the market will reach $5.31 billion by 2030, at a 14.2% CAGR. - The report was published as part of The Business Research Company’s Digital Breast Tomosynthesis Market Report 2026. - The company also said the market is being shaped by stronger breast cancer detection technology and rising awareness of early diagnosis. - A free sample report is available here. - The full report is available here.

The details: - Digital breast tomosynthesis, or DBT, is a 3D mammography method used for breast cancer screening and diagnosis. - DBT captures multiple low-dose X-ray images from different angles and assembles them into a layered 3D view of breast tissue. - The technology is designed to improve abnormality detection, increase early diagnosis accuracy and reduce false positives by limiting overlapping tissue effects. - The report links market growth to rising breast cancer cases, wider adoption of digital mammography equipment, greater public awareness, expansion of diagnostic facilities in hospitals and government screening initiatives. - The report says future demand will be driven by precision oncology diagnostics, AI use in medical imaging, broader use of 3D imaging, expanding screening programs in emerging markets and higher spending on radiology systems. - Anticipated trends include AI-assisted image reconstruction, low-dose imaging techniques, advanced radiology workstations for 3D visualization, more combined 2D/3D mammography units and greater use of portable and mobile tomosynthesis devices. - The report says North America held the largest market share in 2025 because of advanced healthcare infrastructure, widespread use of imaging technology and strong screening programs. - The Asia-Pacific region is expected to post the fastest growth during the forecast period because of higher healthcare investment, rising breast cancer awareness and expanded screening coverage. - The regional analysis also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The forecast suggests DBT is moving from a specialized imaging option toward a broader screening tool as health systems prioritize earlier and more precise cancer detection. - The growing role of AI and portable devices points to a market that is not only expanding, but also shifting toward more flexible and automated workflows. - The strongest growth outside North America may come from markets building screening infrastructure from a lower base.

What’s next: - The report expects continued adoption of AI-assisted reconstruction, portable systems and hybrid 2D/3D mammography platforms. - The Business Research Company said its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and future trend analysis. - Additional related reports cover connected health personal medical devices, contract sterilization and orthotic insole 3-D printers.

The bottom line: - DBT is positioned for steady global expansion as breast cancer screening needs, imaging innovation and healthcare investment keep rising.